Aligos Therapeutics, Inc. (ALGS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Aligos Therapeutics, Inc.'s filing signal continuing negative.

Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for liver diseases and viral infections, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. The company's pipeline features three lead drug candidates: pevifoscorvir sodium for chronic HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections. Pevifoscorvir sodium is a potential best-in-class Capsid Assembly Modulator (CAM-E) showing significant HBV DNA and antigen reductions in Phase 1 studies. ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, demonstrated statistically significant reductions in liver fat in a Phase 2a MASH study. ALG-097558, a protease inhibitor, is a potent pan-coronavirus candidate that does not require ritonavir co-dosing. Aligos leverages its expertise in drug development and medicinal chemistry to advance these candidates through clinical trials.

Revenue is primarily generated from research and development services under third-party contracts and collaboration agreements, with potential for future product sales upon regulatory approval.